Dergiler / European Journal of Therapeutics / 2020 / Cilt: 26 - Sayı: 2

Role of Serum HMGB1 in Prostate Cancer

Sayfa
108–112
DOI
—

Abstract

Purpose: In our study the diagnostic role of HMGB1 levels measured in serum were investigated in prostatitis and prostate carcinoma diagnosis and in the differential diagnosis of these two diseases. Material Method: Patients followed up for histopathologically verified diagnosis of prostate carcinoma and prostatitis in 20142017 at the Urology Clinic were included. HMGB1 measurement in serum was performed with the ELISA method. Results: A total of 78 subjects were included in the study, consisting of 30 (38.5%) prostatitis patients, 25 (32%) prostate carcinoma patients and 23 (29.5%) healthy subjects. HMGB1 was detected as 11.9±2.6 (Range 6.7-18.4) ng/ml in the prostatitis group, 15.1±4.5 (Range 8.4-24.8) ng/ml in the prostate carcinoma patients and as 9.2±3.1 (Range 4.7-18.7) ng/ml in the control group. The difference between the groups were investigated using the Friedman test as HMGB1 did not show normal distribution. Significant difference was detected between the three groups (p